Novavax has received $1.6bn under the US Government’s Operation Warp Speed (OWS) programme to support the development and manufacturing of its Covid-19 vaccine candidate.
Named NVX‑CoV2373, the vaccine is made up of a stable, prefusion protein created using the company’s nanoparticle technology and includes its Matrix‑M adjuvant.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company will use the funding for late-stage clinical development, large-scale manufacturing and to deliver 100 million doses of NVX‑CoV2373 by late 2020.
